Supported Work

2024 Publications

1. Takyi-Williams J, Leino AD, Li R, Downes KJ, Zuppa AF, Bwint A, Wen B, Sun D, Scheetz MH, Pai MP. Bioanalysis of six antibiotics from volumetric microsamples: a new tool for precision dosing in critically ill children. Bioanalysis. 2024 Jan;16(1):19-31.
2. Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, Garcia Moure M, Garton H, Gowda P, Marques JG, Hawkins C, Heath A, Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR, Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M, Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H, Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ, Resnick A, Rogawski D, Saratsis A, Sbergio SG, Souweidane M, Stafford JM, Tzaridis T, Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q, Venneti S. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 Jan 8;42(1):1-5.
3. Zhou W, Zhao Z, Lin A, Yang JZ, Xu J, Wilder-Romans K, Yang A, Li J, Solanki S, Speth JM, Walker N, Scott AJ, Wang L, Wen B, Andren A, Zhang L, Kothari AU, Yao Y, Peterson ER, Korimerla N, Werner CK, Ullrich A, Liang J, Jacobson J, Palavalasa S, O'Brien AM, Elaimy AL, Ferris SP, Zhao SG, Sarkaria JN, Győrffy B, Zhang S, Al-Holou WN, Umemura Y, Morgan MA, Lawrence TS, Lyssiotis CA, Peters-Golden M, Shah YM, Wahl DR. GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress. Cancer Discov. 2024 Jan 12;14(1):158-175.

2023 Publications

1.  Bu Y, Traore MDM, Zhang L, Wang L, Liu Z, Hu H, Wang M, Li C, Sun D. A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis. J Biol Chem. 2023 Dec;299(12):105467. doi: 10.1016/j.jbc.2023.105467. Epub 2023 Nov 17. PMID: 37979913; PMCID: PMC10755797.
2. Yuan X, Jiang H, Fu D, Rech JC, Robida A, Rajanayake K, Yuan H, He M, Wen B, Sun D, Liu C, Chinnaswamy K, Stuckey JA, Paczesny S, Yang CY. Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors. ACS Pharmacol Transl Sci. 2023 Aug 16;6(9):1275-1287.
3. Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D, Lu J, Bai L, Yang CY, Kirchhoff PD, Takyi-Williams J, Wang L, Wen B, Sun D, Ator M, Mckean R, Chinnaiyan AM, Wang S. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. J Med Chem. 2023 Sep 28;66(18):13280-13303.
4. Chen Z, Hu B, Rej RK, Wu D, Acharyya RK, Wang M, Xu T, Lu J, Metwally H, Wang Y, McEachern D, Bai L, Gersch CL, Wang M, Zhang W, Li Q, Wen B, Sun D, Rae JM, Wang S. Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. J Med Chem. 2023 Sep 14;66(17):12559-12585.
5. Yang L, Tu W, Huang L, Miao B, Kaneshige A, Jiang W, Leng L, Wang M, Wen B, Sun D, Wang S. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong <i>in vivo</i> Antitumor Activity. J Med Chem. 2023 Aug 10;66(15):10761-10781.
6. Wang K, Marciani L, Amidon GL, Smith DE, Sun D. Stochastic Differential Equation-based Mixed Effects Model of the Fluid Volume in the Fasted Stomach in Healthy Adult Human. AAPS J. 2023 Jul 27;25(5):76.
7. Han X, Zhao L, Xiang W, Miao B, Qin C, Wang M, Xu T, McEachern D, Lu J, Wang Y, Metwally H, Yang CY, Kirchhoff PD, Wang L, Matvekas A, Takyi-Williams J, Wen B, Sun D, Ator M, Mckean R, Wang S. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2023 Jul 13;66(13):8822-8843.
8. Thomas JE 2nd, Wang M, Jiang W, Wang M, Wang L, Wen B, Sun D, Wang S. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins. J Med Chem. 2023 Jun 22;66(12):8178-8199.
9. Bu Y, Gao R, Zhang B, Zhang L, Sun D. CoGT: Ensemble Machine Learning Method and Its Application on JAK Inhibitor Discovery. ACS Omega. 2023 Mar 27;8(14):13232-13242.
10. Zhang T, Holman J, McKinstry D, Trindade BC, Eaton KA, Castrejon JM, Ho S, Wells E, Yuan H, Wen B, Sun D, Chen GY, Li Y. Corrigendum to "A steamed broccoli sprout diet preparation that reduces colitis via the gut microbiota" [J NutrBiochem 2023;112:109215]. J Nutr Biochem. 2023 Jul;117:109340.
11. Qu P, Rom O, Li K, Jia L, Gao X, Liu Z, Ding S, Zhao M, Wang H, Chen S, Xiong X, Zhao Y, Xue C, Zhao Y, Chu C, Wen B, Finney AC, Zheng Z, Cao W, Zhao J, Bai L, Zhao S, Sun D, Zeng R, Lin J, Liu W, Zheng L, Zhang J, Liu E, Chen YE. DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metab. 2023 May 2;35(5):742-757.
12. Roy J, Kyani A, Hanafi M, Xu Y, Takyi-Williams J, Sun D, Osman EEA, Neamati N. Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. J Med Chem. 2023 Jan 24.
13. Pasternak AL, Park JM, Pai MP. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients. Ther Drug Monit. 2023 Feb 1;45(1):95-101.
14. Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Wang Y, Jiang W, Metwally H, Kirchhoff PD, Zhao L, Jiang H, Wang M, Wen B, Sun D, Stuckey JA, Wang S. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat Chem Biol. 2023 Jun;19(6):703-711.
15. Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Kirchhoff PD, Wen B, Sun D, Stuckey JA, Wang S. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia. J Med Chem. 2023 Feb 23;66(4):2717-2743.
16.  He B, Xiao Y, Liang H, Huang Q, Du Y, Li Y, Garmire D, Sun D, Garmire LX. ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs. Nat Commun. 2023 Feb 22;14(1):993.
17. Yun HG, Smith AJF, DeBacker KC, Pai MP. Estimated glomerular filtration rate with and without race for drug dosing: Cystatin C vs. serum creatinine. Br J Clin Pharmacol. 2023 Mar;89(3):1207-1210.
18. Pai MP, Sitaruno S, Abdelnabi M. Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles. Pharmacotherapy. 2023 Jan;43(1):35-42.
19. Pai MP, Cojutti PG, Gerussi V, Della Siega P, Tascini C, Pea F. Linezolid Population Pharmacokinetics to Improve Dosing in Cardiosurgical Patients: Factoring a New Drug-Drug Interaction Pathway. Clin Infect Dis. 2023 Apr 3;76(7):1173-1179.
20. Pasternak AL, Park JM, Pai MP. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients. Ther Drug Monit. 2023 Feb 1;45(1):95-101.
21. Leino AD, Takyi-Williams J, Pai MP. Volumetric Absorptive Microsampling to Enhance the Therapeutic Drug Monitoring of Tacrolimus and Mycophenolic Acid: A Systematic Review and Critical Assessment. Ther Drug Monit. 2023 Aug 1;45(4):463-478.
22. Jin G, Ho JW, Keeney-Bonthrone TP, Pai MP, Wen B, Ober RA, Dimonte D, Chtraklin K, Joaquin TA, Latif Z, Vercruysse C, Alam HB. Prolonging the therapeutic window for valproic acid treatment in a swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2023 Jun 14.
23. Alikhani R, Pai MP. Reconsideration of the current models of estimated kidney function-based drug dose adjustment in older adults: The role of biological age. Clin Transl Sci. 2023 Sep 13.
24. Liu S, Matvekas A, Naimi T, Ghanem A, Li R, Rajanayake K, Derstine B, Ross B, Sullivan J, Yun HG, Regenbogen S, Byrn J, Su G, Wang S, Pai MP. Morphomics-informed population pharmacokinetic and physiologically-based pharmacokinetic modeling to optimize cefazolin surgical prophylaxis. Pharmacotherapy. 2023 Sep
25. Leino AD, Magee JC, Kershaw DB, Pai MP, Park JM. A comprehensive mixed-method approach to characterize the source of diurnal tacrolimus exposure variability in children: Systematic review, meta-analysis, and application to an existing dataset. J Clin Pharmacol. 2023 Sep 23.
26. Jennaro TS, Puskarich MA, Flott TL, McLellan LA, Jones AE, Pai MP, Stringer KA. Kidney Function as a Key Driver of the Pharmacokinetic Response to High-Dose L-Carnitine in Septic Shock. Pharmacotherapy. 2023 Sep 29
27. Hall RG 2nd, Liu S, Putnam WC, Kallem R, Gumbo T, Pai MP. Optimizing anidulafungin exposure across a wide adult body size range. Antimicrob Agents Chemother. 2023 Nov 15;67(11)
28. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Manzoor H, Lee D, Losser C, Arellano K, Vanhatalo O, Seifert E, Gunewardena A, Wen B, Wang L, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Wu YW, Fineman JR, Ferriero DM, Maltepe E. Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Stroke. 2023 Nov;54(11):2864-2874

2022 Publications

1. Wu F, Mousa Y, Raines K, Bode C, Tsang YC, Cristofoletti R, Zhang H, Heimbach T, Fang L, Kesisoglou F, Mitra A, Polli J, Kim MJ, Fan J, Zolnik BS, Sun D, Zhang Y, Zhao L. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report. CPT Pharmacometrics Syst Pharmacol. 2022 Dec 18.
2. Begley LA, Opron K, Bian G, Kozik AJ, Liu C, Felton J, Wen B, Sun D, Huang YJ. Effects of Fluticasone Propionate on <i>Klebsiella pneumoniae</i> and Gram-Negative Bacteria Associated with Chronic Airway Disease. mSphere. 2022 Dec 21;7(6):e0037722.
3. Leino AD, Takyi-Williams J, Wen B, Sun D, Pai MP. Application of a new volumetric microsampling device for quantitative bioanalysis of immunosuppression. Bioanalysis. 2022 Oct 8.
4. Hu H, Mady Traore MD, Li R, Yuan H, He M, Wen B, Gao W, Jonsson CB, Fitzpatrick EA, Sun D. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054.
5. Yuan X, Jiang H, Fu D, Robida A, Rajanayake K, Yuan H, Wen B, Sun D, Watch BT, Chinnaswamy K, Stuckey JA, Paczesny S, Rech JC, Yang CY. Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease. Bioorg Med Chem. 2022 Oct 1;71:116942.
6. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022 Jul;12(7):3049-3062.
7. Gao W, Hu H, Dai L, He M, Yuan H, Zhang H, Liao J, Wen B, Li Y, Palmisano M, Traore MDM, Zhou S, Sun D. Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety. Acta Pharm Sin B. 2022 May;12(5):2462-2478.
8. Wang K, Li Y, Chen B, Chen H, Smith DE, Sun D, Feng MR, Amidon GL. In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil. Mol Pharm. 2022 Jul 4;19(7):2048 2060.
9. Song Y, Bugada L, Li R, Hu H, Zhang L, Li C, Yuan H, Rajanayake KK, Truchan NA, Wen F, Gao W, Sun D. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci Transl Med. 2022 May 4;14(643):eabl3649.
10. Rom O, Liu Y, Finney AC, Ghrayeb A, Zhao Y, Shukha Y, Wang L, Rajanayake KK, Das S, Rashdan NA, Weissman N, Delgadillo L, Wen B, Garcia-Barrio MT, Aviram M, Kevil CG, Yurdagul A Jr, Pattillo CB, Zhang J, Sun D, Hayek T, Gottlieb E, MorI, Chen YE. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. Redox Biol. 2022 Jun;52:102313.
11. Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. J Med Chem. 2022 Feb 24;65(4):3404-3419.
12. Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. J Med Chem. 2022 Jan 13;65(1):343-368.
13.  Sitaruno S, Santimaleeworagun W, Pattharachayakul S, DeBacker KC, Vattanavanit V, Binyala W, Pai MP. Comparison of Race-Based and Non-Race-Based Equations for Kidney Function Estimation in Critically Ill Thai Patients for Vancomycin Dosing. J Clin Pharmacol. 2022 May 11.
14. Hertz DL, Chen L, Henry NL, Griggs JJ, Hayes DF, Derstine BA, Su GL, Wang SC, Pai MP. Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. Br J Clin Pharmacol. 2022 Jan 26. 
15. Liu S, Pai MP, Lester CA. Medication Use Among U.S. Adults After Bariatric Surgery: A Population-Based Analysis of NHANES 2015-2018. Diabetes Care. 2022 Jan 19:dc212285.
16. Yun HG, Smith AJF, DeBacker KC, Pai MP. Estimated glomerular filtration rate with and without race for drug dosing: Cystatin C vs. serum creatinine. Br J Clin Pharmacol. 2022 Nov 11. 
17. Pai MP, Sitaruno S, Abdelnabi M. Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles. Pharmacotherapy. 2022 Nov 19.
18. Pai MP, Cojutti PG, Gerussi V, Della Siega P, Tascini C, Pea F. Linezolid Population Pharmacokinetics to Improve Dosing in Cardiosurgical Patients: Factoring a New Drug-Drug Interaction Pathway. Clin Infect Dis. 2022 Nov 25

2021 Publications

1. Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec; 74:103725.
2. Pai MP, Crass RL. Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses. Antibiotics (Basel). 2021 Nov 9;10(11):1368. 
3. Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, Sun D, Stuckey JA, Zhou Y, Chen J, Tang G, Wang S. Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. J Med Chem. 2021 Oct 14;64(19):14540-14556. 
4. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rodvold KA, Maples HD. Questions on Vancomycin Dosing. Clin Infect Dis. 2021 Oct 5;73(7):e1777-e1778. 
5. Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2021 Sep 23;64(18):13487-13509. 
6. Han X, Zhao L, Xiang W, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Wang L, Matvekas A, Wen B, Sun D, Wang S. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. J Med Chem. 2021 Sep 9;64(17):12831-12854. 
7. Chen H, Chengalvala V, Hu H, Sun D. Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis. Acta Pharm Sin B. 2021 Aug;11(8):2136-2149. 
8. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D, Deng J, Zhang J. Author Correction: Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2021 Jul 20;11(1):15201. 
9.  Falcone M, Menichetti F, Cattaneo D, Tiseo G, Baldelli S, Galfo V, Leonildi A, Tagliaferri E, Di Paolo A, Pai MP. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother. 2021 Mar 12;76(4):1025-1031.
10.  Wang Y, Xie Y, Niu Y, Song P, Liu Y, Burnett J, Yang Z, Sun D, Ran Y, Li Y, Sun L. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells. Int J Med Sci. 2021 Feb 18;18(8):1753-1759. 
11. Wang H, Ong E, Kao JY, Sun D, He Y. Reverse Microbiomics: A New Reverse Dysbiosis Analysis Strategy and Its Usage in Prediction of Autoantigens and Virulent Factors in Dysbiotic Gut Microbiomes From Rheumatoid Arthritis Patients. Front Microbiol. 2021 Feb 25;12:633732. 
12. Wakam GK, Biesterveld BE, Pai MP, Kemp MT, O'Connell RL, Williams AM, Srinivasan A, Chtraklin K, Siddiqui AZ, Bhatti UF, Vercruysse CA, Alam HB. Administration of valproic acid in clinically approved dose improves neurologic recovery and decreases brain lesion size in swine subjected to hemorrhagic shock and traumatic brain injury. J Trauma Acute Care Surg. 2021 Feb 1;90(2):346-352. 
13. Pai MP. Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity. Clin Pharmacol Ther. 2021 Apr;109(4):942-951. doi:10.1002/cpt.2181.
14. Ali RA, Gandhi AA, Dai L, Weiner J, Estes SK, Yalavarthi S, Gockman K, Sun D, Knight JS. Antineutrophil properties of natural gingerols in models of lupus. JCI Insight. 2021 Feb 8;6(3):138385.
15. Huddle BC, Grimley E, Chtcherbinine M, Buchman CD, Takahashi C, Debnath B, McGonigal SC, Mao S, Li S, Felton J, Pan S, Wen B, Sun D, Neamati N, Buckanovich RJ, Hurley TD, Larsen SD. Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. Eur J Med Chem. 2021 Feb 5;211:113060.
16. Auriti C, Goffredo BM, Ronchetti MP, Piersigilli F, Cairoli S, Bersani I, Dotta A, Bagolan P, Pai MP. High-dose micafungin in neonates and young infants with invasive candidiasis: results of a phase 2 study. Antimicrob Agents Chemother. 2021 Feb 8:AAC.02494-20.
17. He M, Souza E, Matvekas A, Crass RL, Pai MP. Alteration in the Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model. Antimicrob Agents Chemother. 2021 Feb 1:AAC.02141-20.
18. Pai MP. Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Kidney Function. Clin Pharmacol Ther. 2021 Feb 1.
19. Pai MP, Wilcox MH, Chitra S, McGovern PC. Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections. J Antimicrob Chemother. 2021 Jan 17:dkaa558.
20. Liu Y, Hur J, Chan WKB, Wang Z, Xie J, Sun D, Handelman S, Sexton J, Yu H, He Y. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection. Sci Data. 2021 Jan 13;8(1):16.
21. Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 May 14;12(1):2792.
22. Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, Wen B, Wang M, Yang CY, Meagher JL, Sun D, Stuckey JA, Wang S. SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. ACS Med Chem Lett. 2021 May 10;12(6):996-1004.
23. Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, Sun D. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials. 2021 Aug;275:120910.
24. Liu Y, Zhao Y, Shukha Y, Lu H, Wang L, Liu Z, Liu C, Zhao Y, Wang H, Zhao G, Liang W, Fan Y, Chang L, Yurdagul A Jr, Pattillo CB, Orr AW, Aviram M, Wen B, Garcia-Barrio MT, Zhang J, Liu W, Sun D, Hayek T, Chen YE, Rom O. Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. Cell Rep. 2021 Jul 27;36(4):109420.
25. Ravi K, Franson A, Homan MJ, Roberts H, Pai MP, Miklja Z, He M, Wen B, Benitez LL, Perissinotti AJ, Bixby DL, Koschmann C, Marini BL. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. Leuk Lymphoma. 2021 Aug;62(8):1990-1994.
26. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Beringer AW, Rodvold KA, Maples HD. Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. Am J Health Syst Pharm. 2021 Jul 22;78(15):1364-1367.
27. Biesterveld BE, O'Connell R, Kemp MT, Wakam GK, Williams AM, Pai MP, Alam HB. Validation of intraosseous delivery of valproic acid in a swine model of polytrauma. Trauma Surg Acute Care Open. 2021 Mar 17;6(1):e000683.
28. Pai MP, Wilcox M, Chitra S, McGovern P. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial. Respir Med. 2021 Aug;184:106442.
29. Homan MJ, Franson A, Ravi K, Roberts H, Pai MP, Liu C, He M, Matvekas A, Koschmann C, Marini BL. Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. Cancer Chemother Pharmacol. 2021 Sep;88(3):555-562.
30. Hsu CH, Tiba MH, McCracken BM, Colmenero CI, Pickell Z, Leander DC, Weitzel AM, Raghunayakula S, Liao J, Jinka T, Cummings BC, Pai MP, Alam HB, Ward KR, Sanderson TH, Neumar RW. Dose optimization of early high-dose valproic acid for neuroprotection in a swine cardiac arrest model. Resusc Plus. 2020 Jun 1;1-2:100007.
31. Crass RL, Al Naimi T, Wen B, Souza E, Murray S, Pai MP, Jia S. Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2021 Jul 12:AAC0079221.

2020 Publications

1. Falcone M, Menichetti F, Cattaneo D, Tiseo G, Baldelli S, Galfo V, Leonildi A, Tagliaferri E, Di Paolo A, Pai MP. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother. 2020 Dec 30:dkaa549.
2. Morley VJ, Kinnear CL, Sim DG, Olson SN, Jackson LM, Hansen E, Usher GA, Showalter SA, Pai MP, Woods RJ, Read AF. An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. Elife. 2020 Dec 1;9:e58147.
3. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Beringer AW, Rodvold KA, Maples HD. Questions on Vancomycin dosing. Clin Infect Dis. 2020 Nov 26:ciaa1775.
4. Wakam GK, Biesterveld BE, Pai MP, Kemp MT, O'Connell RL, Williams AM, Srinivasan A, Chtraklin K, Siddiqui AZ, Bhatti UF, Vercruysse CA, Alam HB. Administration of valproic acid in clinically approved dose improves neurologic recovery and decreases brain lesion size in swine subjected to hemorrhagic shock and traumatic brain injury. J Trauma Acute Care Surg. 2021 Feb 1;90(2):346-352.
5. Biesterveld BE, Pumiglia L, Iancu A, Shamshad AA, Remmer HA, Siddiqui AZ, O'Connell RL, Wakam GK, Kemp MT, Williams AM, Pai MP, Alam HB. Valproic acid treatment rescues injured tissues after traumatic brain injury. J Trauma Acute Care Surg. 2020 Dec;89(6):1156-1165.
6. Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet. 2020 Nov;59(11):1317-1334.
7. Jennaro TS, Puskarich MA, McCann MR, Gillies CE, Pai MP, Karnovsky A, Evans CR, Jones AE, Stringer KA. Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis. Pharmacotherapy. 2020 Sep;40(9):913-923.
8. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020 Sep 12;71(6):1361-1364.
9. Mehta RK, Pal S, Kondapi K, Sitto M, Dewar C, Devasia T, Schipper MJ, Thomas DG, Basrur V, Pai MP, Morishima Y, Osawa Y, Pratt WB, Lawrence TS, Nyati MK. Low dose Hsp90 inhibitor selectively radiosensitizes HNSCC and Pancreatic xenografts. Clin Cancer Res. 2020 Jul 27:clincanres.3102.2019.
10. Pai MP, DeBacker KC. Modeling Kinetic Glomerular Filtration Rate in Adults with Stable and Unstable Kidney Function: Vancomycin as the Motivating Example. Pharmacotherapy. 2020 Jul 8.
11. Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar HA, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SES, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest. 2020 Jun 30:133310.
12. Souza E, Felton J, Crass RL, Hanaya K, Pai MP. Development of a sensitive LC-MS/MS method for quantification of linezolid and its primary metabolites in human serum. J Pharm Biomed Anal. 2020 Jan 30;178:112968.
13. Rodvold KA, Burgos RM, Tan X, Pai MP. Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet. 2020 Apr;59(4):409-425.
14. Souza E, Crass RL, Felton J, Hanaya K, Pai MP. Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00027-20.
15. Pai MP, DeBacker KC. Modeling Kinetic Glomerular Filtration Rate in Adults with Stable and Unstable Kidney Function: Vancomycin as the Motivating Example. Pharmacotherapy. 2020 Jul 8.
16. Wubben TJ, Pawar M, Weh E, Smith A, Sajjakulnukit P, Zhang L, Dai L, Hager H, Pai MP, Lyssiotis CA, Besirli CG. Small molecule activation of metabolic enzyme pyruvate kinase muscle isozyme 2, PKM2, circumvents photoreceptor apoptosis. Sci Rep. 2020 Feb 19;10(1):2990.
17. Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, Sun D, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med. 2020 Dec 2;12(572):eaaz2841.
18. Chen J, Zhou Y, Dong X, Liu L, Bai L, McEachern D, Przybranowski S, Yang CY, Stuckey J, Li X, Wen B, Zhao T, Sun S, Sun D, Jiao L, Jing Y, Guo M, Yang D, Wang S. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. J Med Chem. 2020 Nov 25;63(22):13994-14016.
19. Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3. ACS Chem Neurosci. 2020 Oct 21;11(20):3464-3473.
20. Hu S, Sechi M, Singh PK, Dai L, McCann S, Sun D, Ljungman M, Neamati N. A Novel Redox Modulator Induces a GPX4-mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species. J Med Chem. 2020 Aug 18.
21. Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. Nanomedicine. 2020 Jul 30:102278.
22. Li Y, Palmisano M, Sun D, Zhou S. Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies. Clin Pharmacol. 2020 Jul 1;12:83-96.
23. Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Fernandez-Salas E, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, Sun D, Stuckey J, Zhou Y, Chen J, Tang G, Wang S. EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. J Med Chem. 2020 Jul 9;63(13):7252-7267.
24. Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Mol Pharm. 2020 Jul 6;17(7):2275-2286.
25. Sun D. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit. AAPS J. 2020 May 26;22(4):77.
26. Liu X, Wilson MW, Liu K, Lee P, Yeomans L, Hagen SE, Lin CM, Wen B, Sun D, White AD, Showalter HD, Antonetti DA. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. Bioorg Med Chem. 2020 Apr 3:115480.
27. Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin. Oncogene. 2020 Apr;39(14):3015-3027
28. Zwicker JD, Smith D, Guerra AJ, Hitchens JR, Haug N, Vander Roest S, Lee P, Wen B, Sun D, Wang L, Keep RF, Xiang J, Carruthers VB, Larsen SD. Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS. ACS Chem Neurosci. 2020 Feb 18. 
29. Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber T, Choi S, Sun D, Ren P, Li LS, Liu Y, Burrows F, Maillard I, Cierpicki T, Grembecka J. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020 Jan 21. pii: 129126. 

2019 Publications

1. Zhou H, Bai L, Xu R, Zhao Y, Chen J, McEachern D, Chinnaswamy K, Wen B, Dai L, Kumar P, Yang CY, Liu Z, Wang M, Liu L, Meagher JL, Yi H, Sun D, Stuckey JA, Wang S. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein. J Med Chem. 2019 Dec 26;62(24): 11280-11300.
2. Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, Chen J, Yang CY, Liu Z, Wang M, Liu L, Jiang H, Wen B, Kumar P, Meagher JL, Sun D, Stuckey JA, Wang S. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.
3. Yu A, Koenigsknecht MJ, Hens B, Baker JR, Wen B, Jackson TL, Pai MP, Hasler W, Amidon GL, Sun D. Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS J. 2019 Nov 11;22(1):3.
4. Shu P, Zhao T, Wen B, Mendelsohn-Victor K, Sun D, Friese CR, Pai MP. Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers. J Oncol Pharm Pract. 2019 Sep 4:1078155219870591.
5. Li, F., Yuan, H., Zhang, H., He, M., Liao, J., Chen, N., Li, Y., Zhou, S., Palmisano, M., Yu, A., Pai, M. & Sun, D. Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. Mol Pharm 16, 2385-2393 (2019)
6. Kahl, D.J., Hutchings, K.M., Lisabeth, E.M., Haak, A.J., Leipprandt, J.R., Dexheimer, T., Khanna, D., Tsou, P.S., Campbell, P.L., Fox, D.A., Wen, B., Sun, D., Bailie, M., Neubig, R.R. & Larsen, S.D. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. J Med Chem 62, 4350-4369 (2019) PMC6590913.
7. Seekatz, A.M., Schnizlein, M.K., Koenigsknecht, M.J., Baker, J.R., Hasler, W.L., Bleske, B.E., Young, V.B. & Sun, D. Spatial and Temporal Analysis of the Stomach and Small-Intestinal Microbiota in Fasted Healthy Humans. mSphere 4(2019) PMC6416366.
8. Gan, X., Wilson, M.W., Beyett, T.S., Wen, B., Sun, D., Larsen, S.D., Tesmer, J.J.G., Saltiel, A.R. & Showalter, H.D. Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes. J Labelled Comp Radiopharm 62, 202-208 (2019) PMC6525014.
9. Dai, W., Samanta, S., Xue, D., Petrunak, E.M., Stuckey, J.A., Han, Y., Sun, D., Wu, Y. & Neamati, N. Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. J Med Chem 62, 3068-3087 (2019)
10. Reimers MA, Shango MM, Daignault-Newton S, Dedinsky R, Karsies D, Kraft S, Riddle L, Felton JA, Wen B, Gersch C, Rae JM, Redman BG, Alva AS. Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. Invest New Drugs. 2019 Apr;37(2):323-330
11. Baker JR, Dickens JR, Koenigsknecht M, Frances A, Lee AA, Shedden KA, Brasseur JG, Amidon GL, Sun D, Hasler WL. Propagation Characteristics of Fasting Duodeno-Jejunal Contractions in Healthy Controls Measured by Clustered Closely-spaced Manometric Sensors. J Neurogastroenterol Motil. 2019 Jan 31;25(1):100-112.
12. Lasek-Nesselquist, E., Lu, J., Schneider, R., Ma, Z., Russo, V., Mishra, S., Pai, M.P., Pata, J.D., McDonough, K.A. & Malik, M. Insights Into the Evolution of Staphylococcus aureus Daptomycin Resistance From an in vitro Bioreactor Model. Front Microbiol 10, 345 (2019) PMC6413709.
13. Crass, R.L., Rodvold, K.A., Mueller, B.A. & Pai, M.P. Renal Dosing of Antibiotics: Are We Jumping the Gun? Clin Infect Dis 68, 1596-1602 (2019)
14. Crass, R.L., Pai, M.P. & Lodise, T.P., Jr. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? J Antimicrob Chemother 74, 126-129 (2019)
15. Crass, R.L. & Pai, M.P. Estimating Renal Function in Drug Development: Time to Take the Fork in the Road. J Clin Pharmacol 59, 159-167 (2019)
16. Crass, R.L. & Pai, M.P. Pharmacokinetics and Pharmacodynamics of beta-Lactamase Inhibitors. Pharmacotherapy 39, 182-195 (2019)
17. Crass, R.L. & Pai, M.P. Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. Clin Pharmacokinet (2019)
18. Barks, J.D.E., Liu, Y., Wang, L., Pai, M.P. & Silverstein, F.S. Repurposing azithromycin for neonatal neuroprotection. Pediatr Res (2019)
19. Jang SM, Pai MP, Shaw AR, Mueller BA. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy. Crit Care Med. 2019 Aug 8.
20. Biesterveld BE, Williams AM, Pai MP, Dennahy IS, Graham NJ, Chtraklin K, Siddiqui AZ, O'Connell RL, Bhatti UF, Liu B, Russo RM, Li Y, Alam HB. Dose Optimization of Valproic Acid in a Lethal Model of Traumatic Brain Injury, Hemorrhage and Polytrauma in Swine. J Trauma Acute Care Surg. 2019 Aug 5.
21. Rodvold KA, Pai MP. Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. Clin Infect Dis. 2019 Aug 1;69
22. Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrob Agents Chemother. 2019 Jul 25;63(8).

2018 Publications

1. Bermejo, M., Paixao, P., Hens, B., Tsume, Y., Koenigsknecht, M.J., Baker, J.R., Hasler, W.L., Lionberger, R., Fan, J., Dickens, J., Shedden, K., Wen, B., Wysocki, J., Lobenberg, R., Lee, A., Frances, A., Amidon, G.E., Yu, A., Salehi, N., Talattof, A., Benninghoff, G., Sun, D., Kuminek, G., Cavanagh, K.L., Rodriguez-Hornedo, N. & Amidon, G.L. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions. Mol Pharm 15, 5454-5467 (2018)
2. Bland, C.M., Pai, M.P. & Lodise, T.P. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Pharmacotherapy 38, 1229-1238 (2018)
3. Cojutti, P., Pai, M.P. & Pea, F. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clin Pharmacokinet 57, 989-1000 (2018)
4. Crass, R.L., Dunn, R., Hong, J., Krop, L.C. & Pai, M.P. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother 73, 3081-3086 (2018)
5. Hens, B., Sinko, P.D., Job, N., Dean, M., Al-Gousous, J., Salehi, N., Ziff, R.M., Tsume, Y., Bermejo, M., Paixao, P., Brasseur, J.G., Yu, A., Talattof, A., Benninghoff, G., Langguth, P., Lennernas, H., Hasler, W.L., Marciani, L., Dickens, J., Shedden, K., Sun, D., Amidon, G.E. & Amidon, G.L. Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project. Int J Pharm 548, 120-127 (2018)
6. Huddle, B.C., Grimley, E., Buchman, C.D., Chtcherbinine, M., Debnath, B., Mehta, P., Yang, K., Morgan, C.A., Li, S., Felton, J., Sun, D., Mehta, G., Neamati, N., Buckanovich, R.J., Hurley, T.D. & Larsen, S.D. Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy. J Med Chem 61, 8754-8773 (2018) PMC6477540.
7. Li, Y.F., Zhang, C., Zhou, S., He, M., Zhang, H., Chen, N., Li, F., Luan, X., Pai, M., Yuan, H., Sun, D. & Li, Y. Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. Clin Pharmacol 10, 165-174 (2018) PMC6235005.
8. Madak, J.T., Cuthbertson, C.R., Miyata, Y., Tamura, S., Petrunak, E.M., Stuckey, J.A., Han, Y., He, M., Sun, D., Showalter, H.D. & Neamati, N. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase. J Med Chem 61, 5162-5186 (2018)
9. Paixao, P., Bermejo, M., Hens, B., Tsume, Y., Dickens, J., Shedden, K., Salehi, N., Koenigsknecht, M.J., Baker, J.R., Hasler, W.L., Lionberger, R., Fan, J., Wysocki, J., Wen, B., Lee, A., Frances, A., Amidon, G.E., Yu, A., Benninghoff, G., Lobenberg, R., Talattof, A., Sun, D. & Amidon, G.L. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State. Mol Pharm 15, 5468-5478 (2018)
10. Paixao, P., Bermejo, M., Hens, B., Tsume, Y., Dickens, J., Shedden, K., Salehi, N., Koenigsknecht, M.J., Baker, J.R., Hasler, W.L., Lionberger, R., Fan, J., Wysocki, J., Wen, B., Lee, A., Frances, A., Amidon, G.E., Yu, A., Benninghoff, G., Lobenberg, R., Talattof, A., Sun, D. & Amidon, G.L. Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. Eur J Pharm Biopharm 129, 162-174 (2018)
11. Tsume, Y., Patel, S., Fotaki, N., Bergstrm, C., Amidon, G.L., Brasseur, J.G., Mudie, D.M., Sun, D., Bermejo, M., Gao, P., Zhu, W., Sperry, D.C., Vertzoni, M., Parrott, N., Lionberger, R., Kambayashi, A., Hermans, A., Lu, X. & Amidon, G.E. In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS J 20, 100 (2018)
12. Yu, J., Chen, J., Zhao, H., Gao, J., Li, Y., Li, Y., Xue, J., Dahan, A., Sun, D., Zhang, G. & Zhang, H. Integrative proteomics and metabolomics analysis reveals the toxicity of cationic liposomes to human normal hepatocyte cell line L02. Mol Omics 14, 362-372 (2018).
13. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24. PubMed PMID: 29805099.
14.  Zhao Y, Zhou B, Bai L, Liu L, Yang CY, Meagher JL, Stuckey JA, McEachern D, Przybranowski S, Wang M, Ran X, Aguilar A, Hu Y, Kampf JW, Li X, Zhao T, Li S, Wen B, Sun D, Wang S. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. J Med Chem. 2018 Jul 26;61(14):6110-6120. doi: 10.1021/acs.jmedchem.8b00483. Epub 2018 Jul 17. PubMed PMID: 30015487.
15. Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. doi: 10.1021/acs.jmedchem.8b00506. Epub 2018 Jul 18. PubMed PMID: 30019901.
16. Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27. PubMed PMID: 29703818.
17. Pai AB, Pai MP, Meyer DE, Bales BC, Cotero VE, Zheng N, Jiang W. In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations. Regul Toxicol Pharmacol. 2018 Aug;97:17-23. doi: 10.1016/j.yrtph.2018.05.014. Epub 2018 May 29. PubMed PMID: 29857115.
18. Butterfield-Cowper JM, Lodise TP Jr, Pai MP. A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. Pharmacotherapy. 2018 Sep;38(9):981-985. doi: 10.1002/phar.2157. Epub 2018 Jul 12. PubMed PMID: 29906315.
19. Auriti C, Goffredo BM, Ronchetti MP, Piersigilli F, Cairoli S, Bersani I, Dotta A, Pai MP. Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young Infants. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01199-18. doi: 10.1128/AAC.01199-18. Print 2018 Oct. PubMed PMID: 30012764; PubMed Central PMCID: PMC6153827.
20. Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, Yuan H, Sun D. Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. Mol Pharm. 2018 Oct 1;15(10):4505-4516. doi: 10.1021/acs.molpharmaceut.8b00527. Epub 2018 Sep 21. PubMed PMID: 30180593.
21. Crass RL, Pai MP. Estimating Renal Function in Drug Development: Time to Take the Fork in the Road. J Clin Pharmacol. 2018 Sep 5. doi: 10.1002/jcph.1314. [Epub ahead of print] Review. PubMed PMID: 30184267.
22. Crass RL, Rodvold KA, Mueller BA, Pai MP. Renal Dosing of Antibiotics: Are We Jumping the Gun? Clin Infect Dis. 2018 Sep 13. doi: 10.1093/cid/ciy790. [Epub ahead of print] PubMed PMID: 30219824.
23. Crass RL, Pai MP, Lodise TP Jr. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? J Antimicrob Chemother. 2018 Sep 24. doi: 10.1093/jac/dky388. [Epub ahead of print] PubMed PMID: 30252050.
24. Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP, Scheetz MH. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01475-17. doi: 10.1128/AAC.01475-17. Print 2018 Mar.
25. Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr..
26. Eschenauer GA, Carver PL, Patel TS, Lin SW, Klinker KP, Pai MP, Lam SW. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose. Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02566-17. doi: 10.1128/AAC.02566-17. Print 2018
27. Crass RL, Ross BE, Derstine BA, Lichty M, Sullivan JA, Su GL, Wang SC, Pai MP. Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00441-18. doi: 10.1128/AAC.00441-18. Print 2018 Jun.
28.  Zwicker JD, Diaz NA, Guerra AJ, Kirchhoff PD, Wen B, Sun D, Carruthers VB, Larsen SD. Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1972-1980. doi: 10.1016/j.bmcl.2018.03.020. Epub 2018 Mar 9.
29. Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska K, Jin Z, Purohit T, Wen B, He M, Sun D, Cierpicki T, Grembecka J. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. J Med Chem. 2018 Jun 14;61(11):4832-4850. doi: 10.1021/acs.jmedchem.8b00071. Epub 2018 May 23.
30. Paixão P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Löbenberg R, Talattof A, Sun D, Amidon GL. Gastric Emptying and Intestinal Appearance of Nonabsorbable Drugs Phenol Red and Paromomycin in Human Subjects: A Multi-Compartment Stomach Approach. Eur J Pharm Biopharm. 2018 May 29. pii: S0939-6411(18)30404-1. doi: 10.1016/j.ejpb.2018.05.033. [Epub ahead of print]
31. Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects. ​Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.02475-17. doi: 10.1128/AAC.02475-17. 
32. Miglis C, Rhodes NJ, Avedissian S, Kubin CJ, Yin MT, Nelson B, Pai MP, Scheetz MH. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01475-17. doi: 10.1128/AAC.01475-17. [Epub ahead of print] PMID: 29311071

2017 Publications

1. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase 1 dose-escalation trial. Clin Pharmacokinet. 2017 May 11. [Epub ahead of print]. PMID: 28497259
2. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
3. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
4. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
5. Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JP, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. PMCID: PMC5395305
6. Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S. Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. J Med Chem. 2017 Apr 13;60(7):2819-2839. PMCID: PMC5394527
7. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. Discovery of a small-molecule degrader of Bromodomain and Extra-Terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2017 Mar 24. [Epub ahead of print] PMID: 28339196 
8. Patel TS, Cinti S, Sun D, Li S, Luo R, Wen B, Gallagher BA, Stevenson JG. Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile. Am J Infect Control. 2017 Mar 1;45(3):303-305. PMID: 27816215
9. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
10. Luo R, LI Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017 Jan 4;519(1-2):1-10. PMID: 28063903
11. Wagner D, Caraballo M, Waldvogel J, Peterson Y, Sun D. In vitro effects of an extracorporeal membrane oxygenation circuit on the sequestration of ϵ-aminocaproic acid. Perfusion. 2017 Apr;32(3):226-229. PMID: 27815558 
12. Cojutti P, Pai MP, Pea F. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clin Pharmacokinet. 2017 Oct 28. doi: 10.1007/s40262-017-0606-5. [Epub ahead of print] PMID: 29080937 
13. Koenigsknecht MJ, Baker JR, Wen B, Frances A, Zhang H, Yu A, Zhao T, Tsume Y, Pai MP, Bleske BE, Zhang X, Lionberger R, Lee A, Amidon GL, Hasler WL, Sun D. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. Mol Pharm. 2017 Dec 4;14(12):4295-4304. doi: 10.1021/acs.molpharmaceut.7b00425. Epub 2017 Oct 5. PMID: 28937221
14.  Pai MP, Derstine BA, Lichty M, Ross BE, Sullivan JA, Su GL, Wang SC. Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01402-17. doi: 10.1128/AAC.01402-17. Print 2017 Nov. PMID: 28807918 
15. Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study. BMC Infect Dis. 2017 Aug 2;17(1):534. doi: 10.1186/s12879-017-2609-0. PMID: 28764660  
16. Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Lodise TP. Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study. Diagn Microbiol Infect Dis. 2017 Jul;88(3):259-263. doi: 10.1016/j.diagmicrobio.2017.03.008. Epub 2017 Apr 2. PMID: 28449844 
17. Pai MP, Hong J, Krop L. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02490-16. doi: 10.1128/AAC.02490-16. Print 2017 Apr. PMID: 28096158

2016 Publications

1. Borkin D, Pollock J, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, Sun D, Cierpicki T, Grembecka J. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016. PMID: 26744767
2. Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, Ellingrod VL, Kamali M, McInnis M, and Sun D. Identification of non-reported bupropion metabolites in human plasma. Biopharm Drug Disposition. 2016 Dec;37(9):550-560. PMCID: PMC5132048.
3. Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosis. J Pharmacol Exp Ther. 2016 Oct;359(1):11-7. PMCID: PMC5034710
4. Costa MD, Ashraf NS, Fischer S, Yang Y, Schapka E, Joshi G, McQuade TJ, Dharia RM, Dulchavsky M, Ouyang M, Cook D, Sun D, Larsen MJ, Gestwicki JE, Todi SV, Ivanova MI, Paulson HL. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain. 2016 Sept 19 [Epub ahead of print] PMID: 27645800
5. Passalacqua KD, Charbonneau ME, Donato N, Showalter H, Sun D, Wen B, He M, Sun H, O'Riordan M, Wobu C. Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens. American Society for Microbiology. 2016 Jul;60(7):4183-96. PMID: 27139470

2015 Publications

1. Peterson LF, Sun HS, Liu YH, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun DX, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015;125(23):3588-97. PMID: 25814533
2. Friese, CR, Mendelsohn-Victor K, Wen B, Sun D, Sutcliffe K, Yang JJ, Ronis DL, McCullagh MC, DEFENS Study investigators. DEFENS - Drug Exposure Feedback and Education for Nurses' Safety: study protocol for a randomized controlled trial. Trials. 2015 Apr 17;16:171. PMCID: PMC4411718
3. Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of bupropion by carbonyl reductases in liver and intestine. Drug Metab Dispos. 2015;43(7):1019-27. PMID: 25904761
4. Brooks AF, Jackson IM, Shao X, Kropog GW, Sherman P, Quesada CA, Scott PJH. Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid [small beta] aggregation. MedChemComm. 2015;6(6):1065-8. PMCID: PMC4474278
5. Borkin D, He SH, Miao HZ, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang JY, Wen B, Zong HL, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun DX, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. Cancer Cell. 2015;27(4):589-602. PMCID: PMC4415852
6. Friese CR, McArdle C, Zhao T, Sun D, Spasojevic I, Polovich M, McCullagh MC. Antineoplastic Drug Exposure in an Ambulatory Setting: A Pilot Study. Cancer Nurs. 2015 Mar-Apr;38(2):111-7. PMCID: PMC4232489

2014 Publications

1. Larsen MJ, Larsen SD, Fribley A, Grembecka J, Homan K, Mapp A, Haak A, Nikolovska-Coleska Z, Stuckey JA, Sun DX, Sherman DH. The Role of HTS in Drug Discovery at the University of Michigan. Comb Chem High T Scr. 2014;17(3):210-30. PMCID: PMC4166557
2. Kintzel PE, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. Am J Health Syst Pharm. 2014 Dec 1;71(23):2061-5. PMID: 25404598
3. Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S. Pramipexole Derivatives as Potent and Selective Dopamine D-3 Receptor Agonists with Improved Human Microsomal Stability. ChemMedChem. 2014;9(12):2653-60. PMCID: PMC4277207
4. Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z. A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In vitro and In vivo. Mol Cancer Ther. 2014 Mar;13(3):565-75. PMCID: PMC4174574

2013 Publications

1. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013 Jul 11;56(13):5553-61. PMCID: PMC3880646
2. Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 2013;135(19):7223-34. PMCID: PMC3806051
3. Tao Zhang, Yanyan Li, Peng Zou, Jing-yu Yu, Donna McEachern, Shaomeng Wang, and Duxin Sun. Physiologically based pharmacokinetic and pharmacodynamics modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharmaceutics & Drug Disposition. 2013. 34:348-59. PMID: 23813446
4. Zeller J, Turbiak AJ, Powelson IA, Lee S, Sun D, Showalter HD, Fearon ER. Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of beta-catenin/TCF transcription. Bioorg Med Chem Lett. 2013;23(21):5814-20. PMCID: PMC3896216
5. Yestrepsky BD, Xu Y, Breen ME, Li X, Rajeswaran WG, Ryu JG, Sorenson RJ, Tsume Y, Wilson MW, Zhang W, Sun D, Sun H, Larsen SD. Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. Bioorg med Chem. 2013;21(7):1880-97. PMCID: PMC3605901
6. Miyata Y, Li X, Lee HF, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, Gestwicki JE. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci. 2013;4(6):930-9. PMCID: PMC3689201.
7. Li Y, Zhang T, Li X, Zou P, Schwartz SJ, Sun D. Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. Mol Nutr Food Res. 2013 Dec;57(12):2128-36. PMCID: PMC3855579
8. Li X, Srinivasan SR, Connarn J, Ahmad A, Young ZT, Kabza AM, Zuiderweg ER, Sun D, Gestwicki JE. Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents. ACS Med Chem Lett. 2013;4(11):1042-7. PMCID: PMC3845967

2012 Publications

1. Zou P, Zheng N, Yu Y, Yu S, Sun W, McEachem D, Yang Y, Yu LX, Wang S, Sun D. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci. 2012;15(2):265-80. PMID: 22579006
2. Zou P, Zheng N, Yang Y, Yu LX, Sun D. Prediction of Volume of Distribution at Steady-State in Humans: Comparison of Different Approaches. Expert Opinion on Drug Metabolism and Toxicology. 2012;8(7): 855-872 PMID: 22591253
3. Zou P, Yu Y, Zheng N, Yang Y, Paholak HJ, Yu LX, Sun D. Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. AAPS J. 2012;14:262-81. PMCID: PMC3326168

2011 Publications

1. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the Pharmacokinetics of Active Ingredients of Ginger in Humans. AAPS J. 2011, 13(3): 417-26. PMCID: PMC3160151
2. Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, Sun D, Wang S. Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity. J Med Chem. 2011;54:3306. PMCID: PMC3108148
3. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. J Med Chem. 2011;54:2714. PMCID: PMC3520070
4. Zheng N, Zou P, Wang S, Sun D. In Vitro Metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in Human Liver Microsomes. Drug Metab Dispos. 2011;39:627-35. PMCID: PMC3063720

Previous Publications

1. Yanke Yu, Lanyan Fang, Duxin Sun. Biodistribution of HuCC49∆CH2-β-galactosidase in colorectal cancer xenograft model. International J Pharmaceutics. 2010, 386: 208. PMCID: PMC2815147
2. Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mozisik CM, Johnson MA, Knopp MV, Martin EW Jr., Sun D. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World Journal of Surgical Oncology. 2010;8:65. PMCID: PMC2924340
3. Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW, Jr., Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm. 2009;6:428-40. PMCID: PMC2888669.
4. Fang L, Sun D. Predictive physiological based pharmacokinetic (PBPK) analysis for antibody directed enzyme prodrug therapy (ADEPT). Drug Metab and Dispos. 2008;36:1153-65. PMID: 18356268
5. Fang L, Holford NH, Hinkle G, Cao X, Bloomston MP, Xiao JJ, Gibbs S, Al Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Jr., and Sun D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49∆CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. J Clin Pharmacol. 2007;47(2):227-37. PMID: 17244774
6. Xianhua Cao, Seth T. Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho-Chul Shin, Hans Lennernas, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, and Duxin Sun. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharm Res. 2006, 23: 1675
7. Badawy SI, Gray DB, Zhao F, Sun D, Schuster AE, Hussain MA. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res 2006;23(5):989-96. PMID: 16715389. 
8. Rong Zhou, Paul Moench, Christopher Heran, Xujin Lu, Neil Mathias, Teresa Faria, Doris A. Wall, Munir A. Hussain, Ronald L. Smith, and Duxin Sun. pH-Dependent Dissolution In Vitro and Absorption In Vivo of Weakly Basic Drugs: Development of a Canine Model. Pharmaceutical Research. 2005, 22: 188
9. Jim Xiao, Sara Horst, George Hinkle, Xianhua Cao, Ergun Kocak, Jing Fang, Donn Young, M. Khazaeli, Doreen Agnese, Duxin Sun, Edward Martin, Jr. Pharmacokinetics and Clinical Evaluation of 125I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49deltaCH2) in Recurrent and Metastatic Colorectal Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20: 16
10. Xianhua Cao, Lawrence X. Yu, Catalin Barbaciru, Christopher P. Landowski, Ho-Chul Shin, Seth Gibbs, Heather A. Miller, Gordon L. Amidon, and Duxin Sun. Permeability Dominates In Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. Molecular Pharmaceutics. 2005, 2: 329-340
11. Sun D, Yu LX, M. Hussain, RL Smith, Amidon GL, and Smith RL. In Vitro Testing of Drug Absorption for Drug “Developability” Assessment: Forming an Interface Between In Vitro Preclinical Data and Clinical Outcome. Current Opinion in Drug Discovery and Development. 2004, 7 (1): 75-85

Clinical Pharmacokinetics

1. Setting patient-centric quality standards for modified release oral drug products with biopredictive in vitro dissolution models. FDA BAA-20-00123-A2. Co-PI: Duxin Sun, Amit Pai. Co-I: William Hasler, Greg Amidon. 2020-2023.
2. Randomized controlled trial to improve oncology nurses’ protective equipment use. CDC R01 OH010582-01, PI: Christopher Friese, Co-I Duxin Sun. 2014-2018. 
3. Modernization of in vivo-in vitro oral bioperformance prediction and assessment. FDA HHSF223201310144C, Co-PI: Gordon Amidon, Co-PI: Duxin Sun. 2013-2017.
4. Investigation of release profiles of bupropion and pharmacogenomics of metabolism enzymes for bioequivalance of generic bupropion products in healthy volunteers. FDA HHSF223201310144C, PI: Duxin Sun. 2013-2016.
5. Correlation of mesalamine pharmacokinetics with local availability. FDA HHSF223201000082C, HHSF223201300460A, PI: Duxin Sun. 2010-2015.

Preclinical Pharmacokinetics

1.  Assessment of MODS and Personalized Exposures of Antibiotics. HSD of NIH subcontracts GRT-00001597. PI: Amit Pai. 2021-2026.
2. Development of Protein Degraders. Oncopia Therapeutics, Inc. PI: Duxin Sun. 2021-2023.
3. Tissue localization of Cyclosporine and related metabolite in CD-1 mouse models. Aurinia Pharmaceuticals Inc. PI: Duxin Sun. 2020-2022.
4. Nanoformulation of anticancer drugs to eliminate cancer stem cells. NanoMedicine Innovation Center LLC. PI: Duxin Sun. 2019-2021.
5. Drug Optimization altering tissue targeting to improve efficacy/safety. NanoMedicine Innovation Center LLC. PI: Duxin Sun. 2019-2021.
6. Virus-like nanoparticles for non-capsid antigen delivery with virus structure/functional mimicry to activate B-Cell immunity.  NIH R01 AI154072-01. PI: Duxin Sun, Co-PI: Irina Grigorova. 2020-2025.
7. Development of first-in-class ST2 inhibitors for treating graft-versus-host disease. NIH 7R01 HL-141432-02. PI: Chao-Yie Yang, Co-i: Duxin Sun. 2019-2023.
8. Targeting the MLL complex in castration resistant prostate cancer. NIH R01 CA-200660-01-A1. PI: Jolanta Grembecka, Arul Chinnaiyan, Co_I: Duxin Sun. 2016-2021.
9. Development of ASH1L inhibitors for acute leukemia. NIH R01 CA244254. PI: Jolanta Gremecka, Co-I: Duxin Sun. 2019-2024.
10. Small-molecule STAT3 degraders. NIH R01 CA244509. PI: Shaomeng Wang, Co-I: Duxin Sun. 2019-2024.
11. University of Michigan Comprehensive Cancer Center support grant. NIH P30 CA-046592-29. PI: Eric Feiron, Co-I: Duxin Sun (PK SR Director). 2018-2023.
12. Inhibiting Bcl-2 intestinal regulated intestinal fibrosis. NIH R01 DK-118154-01. PI: Peter Higgins, Co-I: Duxin Sun. 2018-2023.
13. Tarketing NSD1 in leukemia. NIH R01 CA-226759-01-A1. PI: Thomasz Cierpicki, Co-I: Duxin Sun. 2018-2023.
14. Hit-to-lead optimization for heart failure drug discovery.  NIH R01 HL-148068-01. PI: Lennane Michel Espinoza-Fonseca, Co-I: Duxin Sun. 2019-2023.
15. Development of a dual and selective small molecule inhibitor of EGFR and PI3 Kinase to treat BRAF mutant colorectal cancer. NIH R01 CA-220199-01-A1. PI: Judith Leopold, Co-I: Duxin Sun. 2018-2023.
16. Targeting the menin-MLL complex for new therapeutics. NIH R01 CA-208267-01-A1. PI: Shaomeng Wang, Co-I: Duxin Sun. 2018-2023.
17. Isozyme-selective ALDH inhibitors for sensitizing ovarian cancer stem-like cells to chemotherapy. NIH R01 CA-214567-01. PI: Scott Larsen, Co-I: Duxin Sun. 2017-2020.
18. Small-molecule MDM2 degraders. NIH R01 CA-217141. PI: Shaomeng Wang, Co-I: Duxin Sun. 2017-2022.
19. Sputum microbial markers of type 2-low asthma. NIH R01 AI129958. PI: Yvonne Huang, Co-I: Duxin Sun. 2017-2022.
20. Novel Mcl-1 inhibitors for overcoming therapeutic resistance is colorectal cancer. NIH R01 CA-217141. PI: Zaneta Nikolovska-Coleska, Co-I: Duxin Sun. 2017-2022.
21. Development of novel anti-leukemia agents targeting the menin-MLL interaction. NIH R01 CA-160467-06. PI:Jolanta Grembecka, Co-I: Duxin Sun. 2017-2022.
22. Small molecule degraders of BET proteins. NIH R01 CA-215758-01. PI: Shaomeng Wang, Co-I: Duxin Sun. 2017-2022.
23. Isozyme-selective ALDH inhibitors for sensitizing ovarian cancer stem-like cells to chemotherapy. NIH R01 CA214567-01. PI: Scott Larsen, Co-I: Duxin Sun. 2017-2020.
24. Tissue distribution and pharmacokinetics of tyrosine kinase inhibitors (TKI). Celgene Corporation.  PI: Duxin Sun.  2016-2019.
25. Development of small-molecule degraders of BET proteins for triple-negative breast cancer.  The Breast Cancer Research Foundation, PI: Shaomeng Wang, Co-I: Duxin Sun. 2016-2018.
26. Pharmacokinetics and tissue distribution of Abraxane. Celgene Corporation, PI: Duxin Sun. 2016-2017
27. Drug tumor distribution impacts efficacy of tamoxifen analogs. Celgene Corporation, PI: Duxin Sun. 2015-2017.
28. Wireless Pharmaceutical Analysis Device (WPAD) and computation model to determine in vivo drug dissolution in GI tract for distinguishing meaningful product differences and ensuring bioequivalence (BE). FDA HHSF223201510146C, PI: Duxin Sun.
29. The development of small molecule inhibitors for Gaucher Disease Type 3. NIH UH2-NS-092981-01, PI: James Shayman, Co-I: Duxin Sun. 2015-2016. 
30. ROS-targeted therapy for pancreatic cancer. NIH R01-CA-188252-01-A1, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
31. Efficacy of PDI inhibitors in glioblastoma. NIH R01 CA193690-01, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
32. Menin-MLL inhibitor program. Kura Oncology, PI: Jolanta Grembecka, Co-I: Duxin Sun. 2015-2018.
33. SPORE in prostate cancer.  NIH 1P50CA186786-01, PI: Arul Chinnaiyan, Co-I: Duxin Sun. 2014-2019. 
34. Targeting host deubiquitinases for broad spectrum anti-infective therapy. NIH R21/R33 AI102106-03, PI: Mary O’Riordan, Co-I: Duxin Sun. 2014-2017. 
35. Enhanced oral delivery of low solubility drugs using cocrystal design. NIH R01 GM107146-01-A1, PI: Nair Rodriguez-Hornedo, Co-I: Duxin Sun. 2014-2018.
36. Inhibition of the Rho/MRTF/SRF pathway as a new treatment for systemic sclerosis. NIH R01 AR066049, PI: Scott D Larsen, Co-I: Duxin Sun. 2014-2017. 
37. Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes. NIH R01 EY023725, PI: David Antonetti, Co-I: Duxin Sun. 2014-2017. 
38. Define and optimize tumor targeting properties to predict preclinical and clinical efficacy of anti-cancer agents. Celgene Corporation, PI: Duxin Sun. 2014-2016.
39. Pharmacokinetics and tumor distribution of different liposomal doxorubicin formulations. Celgene Corporation, PI: Duxin Sun. 2014-2015.
40. BET Bromodomain Inhibitors. Oncofusion Therapeutics, 145038, PI: Shaomeng Wang, Co-I: Duxin Sun. 2014-2015. 
41. Targeted elimination of cancer stem cells for AML therapy. NIH R01 CA171972-01A1, PI: Yang Liu, Co-I: Duxin Sun. 2013-2018. 
42. Targeting the MLL-WDR5 protein-protein interaction. NIH R01 CA177307-01, PI: Shaomeng Wang, Yali Dou, Co-I: Duxin Sun. 2013-2017. 
43. Novel probes for studying treatment of CNS-based lysosomal storage diseases. NIH R01 HD076004-01, PI:  Scott D Larsen, Co-I: Duxin Sun. 2013-2016.  
44. Investigation of inequivalence of buproprion hydrochloride extended release tablets: In vitro metabolism quantification. FDA HHSF223201310183C, PI: Duxin Sun. 2013-2015.    
45. Mechanisms of motor neuron toxicity in Kennedy disease. NIH R01 NS055746-06A1, PI: Andrew Lieberman, Co-I: Duxin Sun. 2012-2017. 
46. Development of novel anti-leukemia agents targeting the menin-MLL interaction. NIH R01 CA160467-01. PI: Jolanta Grembecka, Co-I: Duxin Sun. 2011-2016. 
47. DUB Inhibitors for Treatment of B-cell Malignancies. Lymphoma and Leukemia Society. PI: Nick Donato, Co-I: Duxin Sun. 2012-2013. 
48. Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse. NIH R01 DA032943. PI: Shaomeng Wang, Co-I: Duxin Sun. 2012-2016. 
49. In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor with central nervous system activity. NIH R21 NS079633-01, PI: James Shayman, Co-I: Duxin Sun. 2012-2014.
50. Receptor Na/K-ATPase antagonists as novel therapeutics for renal/cardiac diseases. NIH R01 HL109015-01. PI: ZiJian Xie, Co-I: Duxin Sun. 2011-2015. 
51. Menin-MLL Fusion Inhibitor Program. Lymphoma and Leukemia Society. UM347450 /N013134-03. PI: Jolanta Grembecka,  Co-I: Duxin Sun. 2010-2015. 
52. Chaperones and Small Molecules NIH R01 NS059690-S1, PI: Jason Gestwicki, Co-I: Duxin Sun. 2010-2011. 

1. Shaomeng Wang, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani. BET bromodomain inhibitors and therapeutic methods using the same.

           US patent number 9675697 issued 6/14/2017.

           US patent application15/619,971 filed 6/12/2017.

2. Sheomeng Wang, Yujun Zhao, Bing Zhao, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, and Xu Ran. 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors. 

​           US patent number 9580430 issued 2/28/2017.

           US patent application 14-633,360 filed 2/27/2015.

3. Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li. Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof.

US patent number 9216693 issued 12/22/2015.

US patent application 14/773,686 filed 9/8/2015. 

US patent application 14/937421 filed 11/10/2015.

4. Shaomeng Wang, Jianfang Chen, Donna McEachern, Longchuan Bai, Liu Liu, Duxin Sun, Xiaoqin Li, Angelo Aguilar. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 9096625 issued 7/15/2015.

US patent application 14/816,191 filed 8/3/2015.

5. Shaomeng Wang, Haibin Zhou, Jianfang Chen, Angelo Aguilar, Jennifer Meagher, Duxin Sun, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna J. McEachern, Jeanne A. Stuckey-Cupp, Xiaoqin Li. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 8691184 issued 4/8/2014.

6. Shaomeng Wang, Shanghai Yu, Wei Sun, Sanjeev Kumar Shangary, Duxin Sun, Peng Zou, Donna McEachern, Yujun Zhao. Spiro-oxindole MDM2 antagonists.

US patent number 9079913 issued 6/24/2015.

US patent number 8877796 issued 11/4/2014.

US patent number 8518984 issued 8/27/2013. 

7. Ruijuan Luo, Duxin Sun, Jamie Connarn, Vicki L. Ellingrod, Melvin McInnis. Bupropion metabolites and uses thereof. 

Filed for US provisional patent 3/31/2016.

8. Scott D. Larsen, Akira Abe, Liming Shu, Michael W. Wilson, Richard F. Keep, Duxin Sun, James A. Shayman. Glycosylceramide synthase inhibitors and therapeutic methods using the same.

Filed for US provisional patent 2015.

9. Shaomeng Wang, Yujun Zhao, Bing Zhao, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, and Xu Ran. 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors.

Filed for US provisional patent 2014; US patent application 14/633,360 filed 2/27/2015.

10. Shaomeng Wang, Arul Chinnaiyan, Irfan Asangani, Yujun Zhao, Bing Zhou, Liu Liu, Longchuan Bai, Angelo Aguilar, Donna J. McEachern, Xu Ran, Duxin Sun, Chao-Yie Yang, Ruijuan Luo, Jeanne A. Stuckey, Jennifer Meagher, Xiaoqin Li, Bo Wen, Hacer Karatas, Ting Zhao. BET bromodomain inhibitors and therapeutic methods using the same.

PCT patent application PCT/US2014/022953 filed 3/11/2014.

https://pharmacy.umich.edu/pkcore/Conference%20Poster